Hyperion DeFi (NASDAQ:HYPD) Given New $6.60 Price Target at Cantor Fitzgerald

Hyperion DeFi (NASDAQ:HYPD) had its target price lifted by equities research analysts at Cantor Fitzgerald from $4.00 to $6.60 in a note issued to investors on Wednesday,Benzinga reports. The brokerage presently has an “overweight” rating on the stock. Cantor Fitzgerald’s price objective suggests a potential upside of 113.94% from the stock’s current price.

Other equities research analysts also recently issued research reports about the company. Chardan Capital dropped their price objective on Hyperion DeFi from $8.25 to $7.30 and set a “buy” rating on the stock in a research report on Monday, June 8th. Weiss Ratings upgraded Hyperion DeFi from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Wednesday, June 24th. Finally, Zacks Research lowered Hyperion DeFi from a “hold” rating to a “strong sell” rating in a research report on Monday, March 30th. Two investment analysts have rated the stock with a Buy rating and two have assigned a Sell rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Hold” and an average target price of $6.95.

Hyperion DeFi Trading Down 1.8%

HYPD traded down $0.06 during trading hours on Wednesday, reaching $3.08. 109,179 shares of the company’s stock traded hands, compared to its average volume of 481,194. The firm has a 50-day moving average price of $3.53 and a 200 day moving average price of $3.50. The company has a quick ratio of 1.97, a current ratio of 1.97 and a debt-to-equity ratio of 0.12. Hyperion DeFi has a 52-week low of $2.49 and a 52-week high of $17.18. The firm has a market capitalization of $46.77 million, a PE ratio of -0.31 and a beta of 2.47.

Insider Buying and Selling at Hyperion DeFi

In other news, insider Hyunsu Jung bought 7,000 shares of the business’s stock in a transaction that occurred on Monday, June 1st. The shares were purchased at an average cost of $3.70 per share, with a total value of $25,900.00. Following the transaction, the insider directly owned 1,384,676 shares in the company, valued at approximately $5,123,301.20. The trade was a 0.51% increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. 7.50% of the stock is owned by company insiders.

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of the company. Sanctuary Advisors LLC acquired a new stake in shares of Hyperion DeFi during the fourth quarter worth about $38,000. Nations Financial Group Inc. IA ADV purchased a new position in Hyperion DeFi during the 4th quarter worth approximately $40,000. Price T Rowe Associates Inc. MD purchased a new position in Hyperion DeFi during the 4th quarter worth approximately $73,000. Formidable Asset Management LLC acquired a new stake in Hyperion DeFi during the 4th quarter valued at approximately $83,000. Finally, State Street Corp acquired a new stake in Hyperion DeFi during the 4th quarter valued at approximately $92,000. 25.84% of the stock is owned by institutional investors and hedge funds.

About Hyperion DeFi

Eyenovia, Inc, an ophthalmic technology company, engages in the development of therapeutics based on its proprietary microdose array print platform technology. The company's product candidates include MicroPine, which is in Phase III clinical development program with indications for pediatric myopia progression (near-sightedness); MicroLine, which is in Phase III clinical development program with indications for the improvement in near vision in people with presbyopia; and Mydcombi, which is in Phase III clinical development program with indications for pharmaceutical mydriasis.